- |||||||||| Trial initiation date, Trial primary completion date: ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (clinicaltrials.gov) - Nov 27, 2017
P2, N=60, Not yet recruiting, Initiation date: Oct 2017 --> Jan 2018 | Trial primary completion date: Sep 2027 --> Dec 2027
- |||||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Enrollment open, Trial initiation date: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Nov 20, 2017 P3, N=500, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Dec 2017
- |||||||||| Trial primary completion date: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 13, 2017
P3, N=249, Completed, Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy. Trial primary completion date: Oct 2017 --> Feb 2017
- |||||||||| epirubicin / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: TURBt With Adjuvant Cryoablation to Treat Bladder Cancer (clinicaltrials.gov) - Oct 19, 2017 P=N/A, N=150, Not yet recruiting, Trial primary completion date: Sep 2018 --> Dec 2018 Phase classification: P2 --> P=N/A | Initiation date: Jun 2016 --> Oct 2017 | Trial primary completion date: Jun 2017 --> Oct 2018
- |||||||||| cisplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery: Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS) (clinicaltrials.gov) - Oct 10, 2017 P3, N=788, Active, not recruiting, Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2018
- |||||||||| metformin / Generic mfg.
Trial primary completion date: NeoMET Study in Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Sep 21, 2017 P2, N=200, Recruiting, Recruiting --> Enrolling by invitation Trial primary completion date: Dec 2017 --> Dec 2019
- |||||||||| Trial completion, Phase classification, Enrollment change: PACT-15: Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer (clinicaltrials.gov) - Sep 1, 2017
P2, N=98, Completed, Trial primary completion date: Aug 2017 --> Dec 2009 Active, not recruiting --> Completed | Phase classification: P2/3 --> P2 | N=370 --> 98
- |||||||||| doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Biomarker, Retrospective data, Journal: Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer. (Pubmed Central) - Jun 28, 2017 In survival analysis, there were no differences in OS (P = .137) and DFS (P = .225) between the 2 groups.Adjuvant chemotherapy could provide little benefit to postmenopausal patients with luminal A, node-positive breast cancer, and endocrine therapy alone may help reduce morbidity. Future studies with a large number of patients and longer follow-up time are necessary to determine whether chemotherapy might be avoided in this patient population.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jun 21, 2017 P2, N=401, Active, not recruiting, Active, not recruiting --> Recruiting Trial primary completion date: Nov 2020 --> Mar 2016
|